. 2017 Aug 2;24(10):1288–1300. doi: 10.1177/1352458517721356

Table 6.

Deviation of the miR-21 target genes from the expected ratio of the up-regulated genes in CD4+ T cells from RR-MS and SP-MS patients and HC.

Prediction^a	Comparison^a	DE^b (p-val)	Group^b	UP obs^b (%)	UP exp^b (%)	p-val^b
Jurkat (N = 64)	RR vs HC	0.01	RR	100	53	0.1
		0.05	RR	80	44	0.02
		0.1	RR	86	43	0.001
	RR vs SP	0.01	RR	–	35
		0.05	RR	100	34	0.006
		0.1	RR	78	37	0.01
	SP vs HC	0.01	SP	100	63	0.4
		0.05	SP	100	58	0.1
		0.1	SP	78	56	0.2
TarBase (N = 433)	RR vs HC	0.01	RR	90	53	0.02
		0.05	RR	65	44	0.004
		0.1	RR	61	43	0.002
	RR vs SP	0.01	RR	75	35	0.09
		0.05	RR	64	34	0.004
		0.1	RR	68	37	0.00001
	SP vs HC	0.01	SP	50	63	0.5
		0.05	SP	52	58	0.5
		0.1	SP	52	56	0.6

RR: relapsing-remitting multiple sclerosis; SP: secondary-progressive multiple sclerosis; HC: healthy controls.

Target genes of miR-21 identified in Jurkat T cells (N = 64, 100% present in RNA-seq data) and genes predicted and experimentally validated to be miR-21 targets by TarBase7.0 (N = 433, 88% present in RNA-seq data) were selected for analysis.

Differentially expressed (DE) genes between RR-MS patients (RR; n = 12), SP-MS patients (SP; n = 10), and healthy controls (HC; n = 12) were identified using RNA-seq (significance for calling DE is indicated by DE (p-val)). For each comparison, a deviation of the percentage of the observed up-regulated miR-21 target genes (UP obs), in a given group (Group), from the expected percentage of the up-regulated genes (UP exp) was calculated using a chi-square test (p-val). p-val <0.05 are indicated in bold.